Latest News & Features
Americas
Top contenders named across 20 categories including litigation, prosecution and portfolio management | Nominees include Dechert, Desmarais, Fish & Richardson, Irell & Manella, Sterne Kessler, Mintz, Wilson Sonsini, Banner Witcoff, and Powell Gilbert. 3 March 2025
Careers
Candido, widely recognised as a highly skilled trial lawyer, will augment the firm’s capabilities in the technology and life sciences spaces. 28 February 2025
Europe
The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen. 27 February 2025
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains. 27 February 2025
Europe
Concerns over misuse, side effects and counterfeits are tightening controls on the blockbuster treatments, says Iona Silverman of Freeths. 27 February 2025
Americas
Former Latham & Watkins global vice chair joins the firm as co-chair of its technology transactions practice | New partner brings experience in biotechnology, life sciences, technology, artificial intelligence and sustainable energy. 27 February 2025
Europe
The company’s nine-country ban against a Chinese rival saw the court adopt a broad interpretation of means-plus-function claims, increasing the risk for infringers even if they modify products. Marisa Woutersen unpacks the debate over the UPC’s flexible approach to added matter and the urgency criteria. 25 February 2025
Biotechnology
Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing technology found invalid | Natera also faces separate trade secrets claims from Guardant Health over cancer blood tests. 25 February 2025
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler. 25 February 2025
Americas
British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent infringement | Earlier ruling ‘nullifies a statutory mechanism for expediting access to generic drugs and breaks sharply with precedent on inducement’ says UK pharma company. 20 February 2025